Scientific exchange · Dr. Andrea Abbott

10 Sept 2026 · In person · Dr. Andrea Abbott, Memorial Sloan Kettering · MSL James Whitfield · Vantrexa

ReviewedVeeva CRMENG-0007—

Capture insight from this engagement

Location: Memorial Sloan Kettering
Therapeutic area: Oncology
Country: United States
Stakeholder tier: Tier 1
Strategic objective: SO-VTX-02 · Close the post-progression sequencing evidence gap through a real-world cohort a…
Initiative: Tier 1 thoracic oncology KOL engagement programme
MSL: JWJames WhitfieldSenior MSL, Oncology (US East)
Product: Vantrexa (vantrelimab)

Topics discussed

Brain-metastasis subgroup data
Chemotherapy-free first line

Scientific content used

VOYAGE-1 pivotal data summary

Questions raised

Is there subgroup data for patients with untreated brain metastases?

Notes

Scientific exchange at MSK. Dr. Abbott raised the exclusion of untreated CNS disease in VOYAGE-1 and its effect on first-line choice for ~1/3 of her patients.

Insights captured (1)

Capture insight

INS-0047Critical
Brain-metastasis subgroup data
Multiple US academic centres are reluctant to use vantrelimab in patients with asymptomatic brain metastases because VOYAGE-1 excluded untreated CNS disease. Absence of subgroup or real-world data drives default to chemo-immunotherapy.
Prioritised

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Connect with Clinical Development
Send publication reprint

0 of 2 complete

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 5
Depth of exchange: 2
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0007

Audit history (0)

All create, update and approval events for this record

No audit events in sample data